Maravai Lifesciences Holdings, Inc. (MRVI) · Peers
Maravai Lifesciences Holdings against the 340 other companies here in its SEC industry, Pharmaceutical Preparations. Each figure is the one on the company's own page; the median is the peers', and the rank is among all 341, highest first.
Measure by measure
| Measure | MRVI | Peer median | Rank |
|---|---|---|---|
| Market value | $1.02B | median $242.10M | 108 of 333 |
| P/S | 4.9× | median 6.7× | 165 of 292 |
| FCF yield | -3.5% | median -12.0% | 110 of 319 |
| Gross margin | 34.9% | median 71.4% | 132 of 162 |
| Operating margin | -56.1% | median -38.9% | 120 of 228 |
| Net margin | -37.1% | median -30.0% | 116 of 222 |
| ROIC | -29.5% | median -43.3% | 86 of 182 |
| ROE | -37.8% | median -37.3% | 140 of 276 |
| Revenue growth (4y, yearly) | -30.6% | median 3.9% | 197 of 243 |
| Current ratio | 4.3× | median 3.7× | 146 of 325 |
| Stock pay / revenue | 14.3% | median 11.6% | 127 of 281 |
| Share count change | 4.7% | median 9.0% | 189 of 314 |
Green where Maravai Lifesciences Holdings is on the better side of the median, red where on the worse; no colour where higher is neither, like size or dividend yield.
The peers, largest first
| Company | Market value | P/E | ROIC | Score |
|---|---|---|---|---|
| MRVIMaravai Lifesciences Holdings, Inc. | $1.02B | P/E – | -29.5% | 2.7 |
| LLYELI LILLY & Co | $1.18T | P/E 44.2× | 41.2% | 6.8 |
| JNJJohnson & Johnson | $615.87B | P/E 29.3× | 18.2% | 6.5 |
| ABBVAbbVie Inc. | $504.37B | P/E 79.9× | 25.6% | 5.7 |
| MRKMerck & Co., Inc. | $360.90B | P/E 113.7× | 6.2% | 5.3 |
| NVSNovartis AG ADR | $286.93B | P/E 20.5× | 21.2% | 7.4 |
| AZNAstraZeneca PLC | $256.54B | P/E 25.1× | 14.6% | 7.2 |
| GSKGSK plc | $213.73B | P/E 25.8× | 20.1% | 7.2 |
| ABTAbbott Laboratories | $182.70B | P/E 29.1× | 9.8% | 6.3 |
| NVONovo Nordisk A/S | $171.70B | P/E 11.3× | 31.6% | 7.3 |
| PFEPfizer Inc | $167.74B | P/E 21.6× | – | 5.8 |
| VRTXVertex Pharmaceuticals Inc | $126.66B | P/E 28.8× | 30.2% | 7.3 |
| BMYBristol-Myers Squibb Company | $122.05B | P/E 13.1× | 17.1% | 7.9 |
| REGNRegeneron Pharmaceuticals Inc | $83.82B | P/E 19.4× | 11.5% | 6.8 |
| SNYSanofi | $49.53B | P/E 5.7× | 6.0% | 6.9 |
| TEVATeva Pharma Industries Ltd ADR | $48.36B | P/E 68.5× | 14.8% | 6.3 |
| ONCBeOne Medicines Ltd. | $38.79B | P/E 59.2× | 69.3% | 7.6 |
| RPRXRoyalty Pharma plc | $33.95B | P/E 41.7× | 6.5% | 6.9 |
| ZTSZoetis Inc. | $32.80B | P/E 12.5× | 27.8% | 7.1 |
| ALNYAlnylam Pharmaceuticals Inc | $31.02B | P/E 42.3× | – | 6.6 |
| UTHRUNITED THERAPEUTICS Corp | $22.87B | P/E 17.4× | 29.6% | 7.8 |
| GMABGenmab AS | $22.75B | P/E 23.6× | 8.8% | 6.5 |
| VTRSViatris Inc | $21.43B | P/E 372.0× | -0.3% | 5.5 |
| INSMINSMED Inc | $21.02B | P/E – | -399.1% | 4.8 |
| ASNDAscendis Pharma A/S | $13.96B | P/E – | -20.6% | 4.0 |
| JAZZJazz Pharmaceuticals plc | $13.65B | P/E 14.5× | -4.1% | 6.5 |
| BBIOBridgeBio Pharma, Inc. | $12.98B | P/E – | – | 3.5 |
| CORTCorcept Therapeutics Incorporated | $12.02B | P/E 217.8× | 1.3% | 5.0 |
| ELANElanco Animal Health Inc | $11.77B | P/E – | – | 5.4 |
| SMMTSummit Therapeutics Inc. | $11.67B | P/E – | – | – |
| BMRNBiomarin Pharmaceutical Inc | $10.58B | P/E 145.1× | 1.1% | 4.8 |
| MDGLMadrigal Pharmaceuticals Inc | $10.39B | P/E – | -989.2% | 4.8 |
| CRNXCrinetics Pharmaceuticals, Inc. | $9.01B | P/E – | – | 4.1 |
| CYTKCytokinetics Inc | $8.71B | P/E – | – | 2.3 |
| PTGXProtagonist Therapeutics, Inc | $8.41B | P/E 101.4× | – | 6.8 |
| TGTXTG Therapeutics, Inc. | $8.26B | P/E 18.7× | 13.5% | 5.3 |
| AXSMAxsome Therapeutics, Inc. | $8.23B | P/E – | – | 4.7 |
| ARWRArrowhead Pharmaceuticals, Inc. | $7.90B | P/E – | – | 4.5 |
| IONSIonis Pharmaceuticals Inc | $7.14B | P/E – | -74.6% | 2.6 |
| SYRESpyre Therapeutics, Inc. | $7.05B | P/E – | – | 3.2 |
| PRAXPraxis Precision Medicines, Inc. | $6.93B | P/E – | -51.3% | 2.8 |
And 300 smaller ones.
The industry is the Standard Industrial Classification code the company registered with the SEC. It is a broad label: a peer group is a starting point for comparing, not proof that two businesses are alike. None of this is advice.